Cover Image

SARS-CoV-2 vaccination in primary humoral immunodeficiency: experience from a german lung clinic

Introduction: During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. Met...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosendahl, Sophie (Author) , Trudzinski, Franziska (Author) , Polke, Markus (Author) , Herth, Felix (Author) , Kreuter, Michael (Author) , Giese, Thomas (Author)
Format: Article (Journal)
Language:English
Published: May 2025
In: Respiration
Year: 2025, Volume: 104, Issue: 5, Pages: 349-359
ISSN:1423-0356
DOI:10.1159/000543146
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000543146
Get full text
Author Notes:Sophie Rosendahl, Franziska C. Trudzinski, Markus Polke, Felix J.F. Herth, Michael Kreuter, Thomas Giese
Description
Summary:Introduction: During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. Methods: In a tertiary center for pulmonary diseases, we investigated the immune response of 11 patients with primary humoral immunodeficiency and 13 healthy controls on the humoral and cellular level after full vaccination with an mRNA or vector vaccine against SARS-CoV-2. Results: In the majority of patients (73%), we found antibodies against the spike protein above the threshold of positivity. Likewise, patients showed a promising cellular response: the upregulated production of INFγ, TNFα, and CXCL10 by T cells did not differ from the response of healthy controls. Conclusion: These results stress the importance to further discern an adequate immunological correlate of protection and the need to follow the effect of booster immunizations in this population at risk.
Item Description:Veröffentlicht: 19. Dezember 2024
Gesehen am 25.07.2025
Physical Description:Online Resource
ISSN:1423-0356
DOI:10.1159/000543146

Similar Items